tv.qiagenbioinformatics.com

Are you new to QIAGEN Ingenuity Pathway Analysis (IPA) or interested in expanding your skill set? Join us as we learn more on large dataset analysis and knowledge base queries using QIAGEN IPA.

You’ll learn to:

• Upload multiple dataset types (e.g., RNA-seq, proteomics, metabolomics) and perform interactive core/pathway analysis in IPA

• Learn how to interpret different results, including pathways, key regulators, impact on biological functions/diseases and more

• Compare different experimental conditions (e.g., single-cell clusters, disease types) and identify similarities and contrasts

• Generate a network for hypothesis generation, even without a dataset or experimental design

QIAGEN IPA let’s you Analyze, Compare, and Contextualize your data. Now with IPA Interpret leverage the power of AI and get a streamlined report on your differential expression analyses with key interpretations.  Share your report with others and explore the updated graphics capabilities.  Learn more: https://digitalinsights.qiagen.com/products-overview/discovery-insights-portfolio/analysis-and-visualization/qiagen-ipa/qiagen-ipa-interpret/

Learn how to leverage solutions from QIAGEN Digital Insights to discover biomarkers, validate targets, and identify variants.

Attendees will learn to:

1. Locate public studies of interest using OmicSoft DiseaseLand

2. Investigate expression of genes of interest across different treatments, disease states, etc.

3. Identify variants of interest for candidate biomarkers and targets using Human Gene Mutation Database (HGMD)

4. Leverage the QIAGEN Knowledgebase in Ingenuity Pathway Analysis (IPA) to explore and extend findings from OmicSoft DiseaseLand and HGMD

5. Access data from OmicSoft, HGMD and IPA in ways that are helpful for data scientists

While there is great interest in the scientific community to investigate drug targets and biomarkers from public immune-oncology data, such investigation is hindered by the difficulty in finding and combining related datasets to perform large-scale meta-analyses. This webinar will focus on how high-quality curated genomic repositories such as QIAGEN OmicSoft Lands immediately allows in-depth investigations across diverse data sources (GEO, CPTAC, TCGA, GTEx and more) to discover and validate candidate checkpoint inhibitor drug targets and biomarkers.

You will learn how to do the following in the graphical user interface and through APIs:

- Easily identify relevant samples using extensive manually curated clinical metadata

- Visualize and identify checkpoint inhibition biology related drug target and biomarkers expression patterns using expression data (RNA-seq, scRNA-seq, proteomics etc.)

- Reveal how the expression of a group of biomarkers (or genes/proteins of interest) correlates in normal and disease tissue

This webinar will introduce users to the long read support plugin for Oxford Nanopore and PacBio sequencing reads in QIAGEN CLC Genomics Workbench.

Participants will learn how to:

• Download and install needed plugins

• Import data required for the analysis

• Perform long read de novo assembly

• Map reads to a reference and visualize an assembly

• Use BLAST to investigate the contigs

• Use additional long read tools: polish with short reads, structural variant calling

• Use genome finishing tools: analyze and assemble contigs

• Use analytical tools: RNA-seq analysis for long reads, classify long read amplicons for metagenomics

QIAGEN Pharmacogenomic Insights (PGXI) is a new knowledgebase designed to help scientific and translational researchers better understand how an individual's genetic make-up influences their response to medications.

Built upon a legacy platform used to deliver more than 1.6 million PGx annotations for more than 250 clinical research laboratories, PGXI provides a streamlined and automated approach that enables labs to efficiently and confidently produce evidence-backed insights for pharmacogenomic markers.

Why is PGXI a game-changer for PGx programs?

• Expert-curated content - Contains expert-curated data from all established PGx information sources, including the FDA, CPIC, DPWG, PharmVar, and PubMed, to provide accurate, up-to-date evidence in one centralized location.

• Automated PGx annotation – Users submit PGx test results to PGXI and rapidly query and identify relevant gene-drug associations and conditions linked to specific genotypes.

• Easy, fast, and scalable - Unlike manual or semi-automated approaches to PGx annotation that can take hours or days, PGXI reduces turnaround time to minutes and eliminates the high cost of maintaining bioinformatic and technical support.

Want to try PGXI for free? Learn more about this new knowledgebase and request a free trial here.

Get to know the RNA-seq Analysis Portal, a cloud-based platform you can access from within QIAGEN Ingenuity Pathway Analysis (IPA) that helps you analyze your RNA-seq expression data. Its predefined analysis pipelines let you calculate expression levels and identify differential expression and significant pathways, regulators, diseases and functions in just a few steps. The graphical views and interactive plots enable seamless exploration and refinement of your RNA-seq analysis results.

In this training you will learn how to

• Upload your own expression data (example raw FASTQ files) or start with a public dataset

• Perform RNA-seq analysis and generate outputs such as heatmap, differential expression table, volcano plot and more

• Export graphical and tabular results

With the increasing accessibility and affordability of next-generation sequencing (NGS), the copious amounts of data from NGS tests and experiments seem endless. The bottleneck has since shifted to interpreting these results: accurate results lessen manual review, while short turnaround times equate to timely diagnoses and patient care.

Back by popular demand, we’ve designed this training to help you master the skills needed to get the most out of Human Gene Mutation Database (HGMD) Professional and its high-quality genetic variant data. Become more proficient at:

• Distinguishing clinically significant variants from VUS